Building a credibility-based framework for target discovery: Perspectives from tRNA synthetase-linked metabolic diseases

构建基于可信度的靶点发现框架:来自tRNA合成酶相关代谢疾病的视角

阅读:1

Abstract

While target identification is essential for successful drug discovery, no systematic workflow exists to prioritize potential targets for a given indication. Therefore, this study aims to develop an information-based approach combining text mining, network analysis, and centrality-based prioritization. As a case study, we applied this workflow to identify metabolic disease targets potentially linked to aminoacyl-tRNA synthetases (ARSs). From 1,407,654 PubMed articles, potential ARS interactors and their disease associations were mined. Using these data, the ARS interactor-disease networks were constructed based on edge frequency and citation count. To assess the reliability of these linkages, we used five centrality indices with novel visualization tools and identified 94 high-credibility disease-associated ARS interactors. Among them, two targets (ESR1 and APP) were selected for experimental validation. Although demonstrated in ARS-mediated metabolic diseases, this approach can be similarly used to identify disease-associated factors with credibility scores within any target space of interest.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。